Reply To: Traders Market Weekly: A Wonderful Life for Central Bankers

#54124
Truman
Participant

Reata Pharmaceuticals, Inc. (RETA 86.48, +55.31, +177.4%): Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia

  • This reply was modified 1 year, 3 months ago by TradersCom.